American Association for Cancer Research
Browse

Supplementary Materials and Methods from A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

Download (134.5 kB)
journal contribution
posted on 2023-03-31, 00:00 authored by Ruth C. Travis, Paul N. Appleby, Richard M. Martin, Jeff M.P. Holly, Demetrius Albanes, Amanda Black, H. Bas Bueno-de-Mesquita, June M. Chan, Chu Chen, Maria-Dolores Chirlaque, Michael B. Cook, Mélanie Deschasaux, Jenny L. Donovan, Luigi Ferrucci, Pilar Galan, Graham G. Giles, Edward L. Giovannucci, Marc J. Gunter, Laurel A. Habel, Freddie C. Hamdy, Kathy J. Helzlsouer, Serge Hercberg, Robert N. Hoover, Joseph A.M.J.L. Janssen, Rudolf Kaaks, Tatsuhiko Kubo, Loic Le Marchand, E. Jeffrey Metter, Kazuya Mikami, Joan K. Morris, David E. Neal, Marian L. Neuhouser, Kotaro Ozasa, Domenico Palli, Elizabeth A. Platz, Michael N. Pollak, Alison J. Price, Monique J. Roobol, Catherine Schaefer, Jeannette M. Schenk, Gianluca Severi, Meir J. Stampfer, Pär Stattin, Akiko Tamakoshi, Catherine M. Tangen, Mathilde Touvier, Nicholas J. Wald, Noel S. Weiss, Regina G. Ziegler, Timothy J. Key, Naomi E. Allen

Supplementary material and methods: supplementary information on data collection, statistical analyses, and presentation of results in the figures.

Funding

Cancer Research UK

NCI

NHLBI

NIA

NIH

Australian NHMRC

NHS

History

ARTICLE ABSTRACT

The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from 17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16–1.43) for IGF-I, 0.81 (0.68–0.96) for IGFBP-1, and 1.25 (1.12–1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. After mutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288–300. ©2016 AACR.

Usage metrics

    Cancer Research

    Categories

    Keywords

    BiomarkersSerum biomarkersCarcinogenesisHormonal carcinogenesisEndocrinologyGrowth factors and receptorsEndogenous Risk FactorsHormonalGenitourinary CancersProstate cancer

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC